8.2 C
New York
Thursday, March 28, 2024

Amgen Reports Stellar Earnings, Raises Guidance

Courtesy of Benzinga.

Related AMGN
Earnings Scheduled For July 29, 2014
Benzinga Weekly Preview: FOMC In Focus As Earnings Season Progresses
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Amgen (NASDAQ: AMGN) moved higher after-hours Tuesday following a mixed quarterly earnings report, but stellar guidance.

Amgen reported GAAP EPS growth of 22 percent, EPS grew from $1.65 in Q2 2013 to $2.01 in Q2 2014. Consensus EPS estimates (adjusted) for Q2 2014 were $2.07; the company reported (adjusted) EPS of $2.37, resulting in a $0.30 beat.

Key drug products like Enbrel, Kyprolis, Prolia and XGEVA contributed to top line growth, and bottom line improvements came as a result of cost reduction in SG&A, and R&D.

Revenue grew by 11 percent year over year, as Q2 2013 revenue increased from $4.67 billion to $5.18 billion in Q2 2014. Analyst consensus revenue estimates were $4.98 billion.

Amgen's full year EPS guidance improved from a range of $7.90-$8.20 to $8.20-$8.40. The company raised its full year 2014 sales outlook from a range of $19.2 billion -$19.6 billion to $19.5 billion – $19.7 billion.

Amgen raised its guidance on top-line due to an improving drug pipeline along with organic growth; the improvement in bottom line results came as a result of further cost efficiencies (the company expects to reduce headcount by 2,400-2,900 through fiscal year 2015).

The stock is up 4.5 percent in Wednesday's pre-market.

Posted-In: Earnings News Guidance

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,453FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x